Potassium Ion

Potassium Ion

SCHEMBL3411903

CCCCCCCCCOP(=O)([O-])[O-].[K+].[K+]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 known ✓ P30556 1/20 0.56
LPAR3 Q9UBY5 8/20 0.59
LPAR2 Q9HBW0 6/20 0.59
LPAR1 Q92633 3/20 0.59
AKT1 P31749 2/20 0.56
CDC25A P30304 2/20 0.56
LMNA P02545 1/20 0.56
ESR1 P03372 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADRA1A P35348 1/20 0.56
KCNH2 Q12809 1/20 0.56
CYP3A4 P08684 1/20 0.50
RECQL P46063 2/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
EPHX2 P34913 1/20 0.47
BLM P54132 1/20 0.47
TERT O14746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL3392001 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL122618 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Hexadecyl Dihydrogen Phosphate SCHEMBL61626 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL27822 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL3851846 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL11137453 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL3409563 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Phosphoric Acid Monotetradecyl Ester SCHEMBL3094298 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL8340229 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A
Potassium Ion SCHEMBL29433163 1.00 LPAR3 (0.59) LPAR3LPAR2LPAR1AKT1CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170283691-A1 QUANTUM DOT-CONTAINING COMPOSITIONS INCLUDING AN EMISSION STABILIZER, PRODUCTS INCLUDING SAME, AND METHOD SAMSUNG ELECTRONICS CO LTD (KR) 2017-10-05 US claimed
US-9701896-B2 Quantum dot-containing compositions including an emission stabilizer, products including same, and method SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-07-11 US claimed
US-20150021521-A1 QUANTUM DOT-CONTAINING COMPOSITIONS INCLUDING AN EMISSION STABILIZER, PRODUCTS INCLUDING SAME, AND METHOD QD VISION, INC. (US) 2015-01-22 US claimed
WO-2013078252-A1 QUANTUM DOT-CONTAINING COMPOSITIONS INCLUDING AN EMISSION STABILIZER, PRODUCTS INCLUDING SAME, AND METHOD QD VISION, INC. (US) 2013-05-30 WO claimed
EP-2234675-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS Schering-Plough Healthcare Products, Inc. (US) 2010-10-06 EP claimed
WO-2009079486-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 2009-06-25 WO claimed
US-20090155194-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. 2009-06-18 US claimed
US-12559611-B2 Hydrophobic alginic acid particle group and method for producing same NISSHINBO HOLDINGS INC. (JP) 2026-02-24 US disclosed
EP-4640751-A1 MARINE BIODEGRADABLE POLYMER PARTICLE GROUPS AND PRODUCTION METHOD FOR SAME Nisshinbo Holdings Inc. (JP) 2025-10-29 EP disclosed
US-12441850-B2 Amphiphilic alginic acid particle group and method for producing same NISSHINBO HOLDINGS INC. (JP) 2025-10-14 US disclosed
CN-118317993-A Marine biodegradable polymer compound, marine biodegradation accelerator, and marine biodegradable resin composition 日清纺控股株式会社 2024-07-09 CN disclosed
CN-118302489-A Marine biodegradation accelerator having two or more monovalent organic anions, and marine biodegradable composition 日清纺控股株式会社 2024-07-05 CN disclosed
WO-2024135121-A1 MARINE BIODEGRADABLE POLYMER PARTICLE GROUPS AND PRODUCTION METHOD FOR SAME 日清紡ホールディングス株式会社 2024-06-27 WO disclosed
US-20120195842-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE MEYER THOMAS A (US) 2012-08-02 US disclosed
EP-2257268-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE Schering-Plough Healthcare Products, Inc. (US) 2010-12-08 EP disclosed
EP-2234675-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS Schering-Plough Healthcare Products, Inc. (US) 2010-10-06 EP disclosed
US-20090232754-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. 2009-09-17 US disclosed
WO-2009108653-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 2009-09-03 WO disclosed
WO-2009079486-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 2009-06-25 WO disclosed
US-20090155194-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120195842-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE TYR, AAAS, ASPH AGTR1 1040/4885LPAR3 4173/4885LPAR2 4579/4885
US-20090155194-A1 ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS TYR, AP2S1, POLL AGTR1 1874/4885LPAR3 4113/4885LPAR2 4159/4885
US-12559611-B2 Hydrophobic alginic acid particle group and method for producing same ALG3, ALG1, HACD3 AGTR1 1788/4885LPAR3 365/4885LPAR2 319/4885
US-20090232754-A1 ENHANCED PHOTOSTABILITY OF SUNCARE COMPOSITIONS CONTAINING AVOBENZONE TYR, ASPH, ALAD AGTR1 1314/4885LPAR3 3357/4885LPAR2 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.